Dental Products Panel Plaque Subcommittee
This article was originally published in The Tan Sheet
Executive Summary
Will meet Dec. 17-18 to discuss "definitions of various terms and conditions related to dental plaque," "the relationship of dental accumulations to oral diseases," and "the data and information which has been submitted relating to drug and cosmetic labeling for antiplaque products," FDA announces in Nov. 16 Federal Register. The meeting will take place in conference room G of FDA's Parklawn Building, beginning at 9 a.m. both mornings.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning